

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jiangxi Rimag Group Co., Ltd.**  
**江西一脉阳光集团股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2522)**

## **VOLUNTARY ANNOUNCEMENT**

### **ACQUISITION OF EQUITY INTEREST IN GAOMAI HEALTH**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Jiangxi Rimag Group Co., Ltd. (the “**Company**”, together with its subsidiaries collectively referred to as the “**Group**”) on a voluntary basis to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company of the latest business developments of the Group.

The Board is pleased to announce that on June 22, 2025, Jiangxi Ganjiang New Area Rimag Health Management Limited (江西贛江新區一脉陽光健康管理有限公司) (“**Rimag Health Management**”) (a wholly-owned subsidiary of the Company, as the purchaser), Guangdong Gaoshang Health Technology Group Co., Ltd. (廣東高尚健康科技集團有限公司) (“**Seller I**”), Xiamen Gaoshang Medical Imaging Diagnostic Center Co., Ltd. (廈門高尚醫學影像診斷中心有限公司) (“**Seller II**”) and Hefei Gaoshang Medical Imaging Diagnostic Center Co., Ltd. (合肥高尚醫學影像診斷中心有限公司) (“**Seller III**”) (as the sellers, collectively referred to as the “**Sellers**”) and Guangzhou Gaomai Health Technology Co., Ltd. (廣州高脈健康科技有限公司) (“**Gaomai Health**”) entered into an equity transfer agreement (the “**Equity Transfer Agreement**”), pursuant to which Rimag Health Management will acquire 30.0%, 20.0% and 20.0% of the equity interest in Gaomai Health from Seller I, Seller II and Seller III, respectively (the “**Acquisition**”), at a total consideration of RMB54,000,000.

As at the date of this announcement, Rimag Health Management does not own any equity interest in Gaomai Health and Gaomai Health is owned as to 60.0% by Seller I, 20.0% by Seller II and 20.0% by Seller III. Upon completion of the Acquisition, Rimag Health Management will own 70.0% equity interest in Gaomai Health, Gaomai Health will be a subsidiary of the Company and its financial results will be consolidated into the financial statements of the Group.

Gaomai Health is a company incorporated under the laws of the PRC with limited liability and is primarily engaged in nuclear medical imaging technology and operation and management services. As two leading companies in China's third-party medical imaging services industry, the Company and Seller I, following the execution of the comprehensive strategic cooperation agreement in January 2025, have further deepened collaboration through the Acquisition to achieve a powerful alliance. This partnership will leverage both parties' expertise and strengths to jointly explore significant historical opportunities in the third-party medical imaging services industry through innovative business models, professional medical teams, and cutting-edge specialized technologies. Specifically, (1) through the Acquisition, the Group will supplement and strengthen its capabilities in the development, management, and operation of nuclear medicine projects by leveraging the accumulated project resources, disciplinary expertise and professional experience of Seller I in the field of nuclear medicine over the years. Both parties are committed to exploring and establishing innovative investment, operation, and promotion models for hospital nuclear medicine projects; (2) both parties will jointly promote the application of new radioactive drug synthesis in the promotion of PET/CT business. Capitalizing on Seller I's strengths in the development and production capabilities of radioactive drugs, and utilizing the Group's deep integration in the medical imaging industry chain, both parties will further promote new technologies, methods and applications of radioactive drugs in the field of nuclear medicine, improving the precision diagnosis capabilities of nuclear medicine; (3) both parties will jointly utilize each other's brand advantages, professional resources, and industry channels to jointly promote the third-party medical imaging center market. Both parties are committed to deepening strategic initiatives, including integrating online prescription issuance and offline examination under internet hospital imaging services, expanding the overseas market for medical imaging services and related product capabilities, deepening regional nuclear medicine business development under the "one county, one nuclear medicine department (一縣一核醫學科)" policy, promoting innovative medical imaging service offerings, discovering the value of medical imaging data assets, and exploring imaging diagnostic AI. Therefore, the Board is of the view that the Acquisition is in the interest of the Company and its Shareholders as a whole.

As all of the applicable percentage ratios (as defined in Rule 14.07 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) in respect of the Acquisition are less than 5%, the Acquisition does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules.

## **INFORMATION OF THE PARTIES**

The Group is a leading medical group specialized in medical imaging in China and the only operator and manager of a medical imaging platform that provides diversified imaging services and value to the entire medical imaging industry chain in China. The Group is principally engaged in the provision of imaging center services, imaging solution services and Rimag Cloud services.

Rimag Health Management is a company incorporated under the laws of the PRC and a wholly-owned subsidiary of the Company. Rimag Health Management is a platform for the Company's industry chain investment integration.

Seller I is a company incorporated under the laws of the PRC with limited liability and primarily engaged in the investment and operation of the medical and healthcare industry. Its ultimate beneficial owner is GAO Xiao (高曉), who ultimately holds 47.0398% equity interest in Seller I on an ultimate look-through basis. Seller II is a company incorporated under the laws of the PRC with limited liability and primarily engaged in independent third-party medical imaging diagnostic services. Its ultimate beneficial owner is GAO Xiao (高曉), who ultimately holds 47.0398% equity interest in Seller II on an ultimate look-through basis. Seller III is a company incorporated under the laws of the PRC with limited liability and primarily engaged in independent third-party medical imaging diagnostic services. Its ultimate beneficial owner is GAO Xiao (高曉), who ultimately holds 47.0398% equity interest in Seller III on an ultimate look-through basis. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, as at the date of this announcement, each of the Sellers and their ultimate beneficial owners are independent third parties of the Company.

**As completion of the Acquisition is subject to the fulfilment (or where applicable, waiver) of the conditions precedent under the Equity Transfer Agreement, it may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Jiangxi Rimag Group Co., Ltd.**  
江西一脈陽光集團股份有限公司  
**Mr. CHEN Zhaoyang**  
*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, June 22, 2025

*As at the date of this announcement, the Board comprises Mr. CHEN Zhaoyang, Ms. HE Yingfei, Mr. FENG Xie and Mr. LI Feiyu as executive Directors, Mr. LIU Senlin and Mr. GUO Tao as non-executive Directors, and Mr. WU Xiaohui, Mr. LUO Yi and Ms. CHEN Yifei as independent non-executive Directors.*